Head

IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Wednesday, April 24, 2024
Cancer, SCCHN, Lung cancer, Neck, Vaccine, PD-1, ASCO, Patient, Society, Melanoma, Head, Annual general meeting, Pharmaceutical industry

NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced the acceptance of an abstract related to IO102-IO103, the company’s lead investigational therapeutic cancer vaccine candidate, for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago May 31-June 4, 2024.

Key Points: 
  • NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced the acceptance of an abstract related to IO102-IO103, the company’s lead investigational therapeutic cancer vaccine candidate, for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago May 31-June 4, 2024.
  • A trial-in-progress poster from the actively recruiting IOB-032/PN-E40 Phase 2 trial (NCT05280314) studying treatment with IO102-IO103 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) given in the perioperative setting in patients with resectable melanoma or squamous cell carcinoma of the head and neck (SCCHN) will be presented.
  • “We are committed to investigating the use of IO102-IO103 combined with PD-1 inhibitors to treat various types of cancer, including melanoma, lung cancer and head and neck cancer,” said Mai-Britt Zocca, Ph.D., President and CEO of IO Biotech.
  • “The IOB-032 Phase 2 study is designed to provide us with insights into treatment outcomes in earlier disease settings with neoadjuvant and adjuvant treatment of patients with melanoma and SCCHN and we look forward to the results of this trial.”

Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO

Retrieved on: 
Wednesday, April 24, 2024
CD3, Cancer, GITR, Multiple myeloma, Safety, Regeneron Pharmaceuticals, Monoclonal antibody, ASCO, CD28, Lymphoma, Patient, Society, Melanoma, Head, Annual general meeting, Pharmaceutical industry

TARRYTOWN, N.Y., April 24, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new and updated data from its oncology and hematology pipeline will be shared across 17 presentations at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, taking place from May 31 to June 5 in Chicago, IL. Notably, new safety and efficacy results from a Phase 1/2 trial investigating the costimulatory bispecific antibody REGN7075 (EGFRxCD28) in combination with Libtayo in patients with certain advanced solid tumors will be featured in an oral presentation.

Key Points: 
  • Notably, new safety and efficacy results from a Phase 1/2 trial investigating the costimulatory bispecific antibody REGN7075 (EGFRxCD28) in combination with Libtayo in patients with certain advanced solid tumors will be featured in an oral presentation.
  • “The breadth of our presentations at ASCO showcase our progress in advancing multiple promising and distinct investigational treatment approaches for a diverse array of difficult-to-treat cancers,” said George D. Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer at Regeneron.
  • “These latest clinical results build on our ongoing commitment to cancer research and reflect our focus on advancing a pipeline of internally-developed candidates that have the potential to offer novel and differentiated therapies.
  • Among them are presentations on updated data and new analyses for linvoseltamab (BCMAxCD3) in multiple myeloma; odronextamab (CD20xCD3) in several lymphoma subtypes; REGN6569 (GITR) in combination with Libtayo across solid tumors; and fianlimab (LAG-3 inhibitor) in combination with Libtayo in non-small cell lung cancer, melanoma and head and neck cancer.

Compass Group Canada Celebrates 9th Annual Stop Food Waste Day, Emphasizing Commitment to Reduce Food Waste by 50% by 2030

Retrieved on: 
Wednesday, April 24, 2024
Education, Head, Meal, Compass Group, Food storage, Culture, Food industry, Food, GHG, CO2, Global warming potential, Organization

Stop Food Waste Day is part of Compass Group Canada’s commitment to reduce food waste by 50% by 2030 and the company’s global Planet Promise to be Net Zero by 2050.

Key Points: 
  • Stop Food Waste Day is part of Compass Group Canada’s commitment to reduce food waste by 50% by 2030 and the company’s global Planet Promise to be Net Zero by 2050.
  • "Stop Food Waste Day has become an iconic event and something we all look forward to at Compass Group Canada,” said Saajid Khan, CEO of Compass Group Canada and ESS North America.
  • To meet their 2030 commitment to reduce food waste by 50%, Compass Group Canada is focused on diverting unused food before it becomes waste and implementing waste mitigation technology.
  • For more information about Stop Food Waste Day and how you can participate in the campaign, visit www.stopfoodwasteday.com .

Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

Retrieved on: 
Wednesday, April 24, 2024
Nephrology, Kidney disease, Kidney, Div, Proteinuria, European Commission, Kidney failure, CHMP, Irbesartan, Immunoglobulin A, European, EGFR, Patient, CSL Vifor, CSL, Committee, Civil service commission, RAAS, Teaching hospital, Head, Therapy, CMA, SAN, Pharmaceutical industry

SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) and CSL Vifor today announced that the European Commission has granted conditional marketing authorization (CMA) for FILSPARI (sparsentan) for the treatment of adults with primary IgA nephropathy (IgAN) with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g). The CMA is granted for all member states of the European Union, as well as in Iceland, Liechtenstein and Norway.

Key Points: 
  • The CMA is granted for all member states of the European Union, as well as in Iceland, Liechtenstein and Norway.
  • “The approval of this innovative treatment is based on data from the only head-to-head phase 3 clinical trial in IgAN.
  • CSL Vifor expects to launch FILSPARI in the first European markets in the second half of 2024.
  • In 2021, Travere Therapeutics granted CSL Vifor exclusive commercialization rights for FILSPARI in Europe, Australia and New Zealand.

Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

Retrieved on: 
Wednesday, April 24, 2024
CPS, Cancer, DCR, HNSCC, Data collection, QOL, Neck, Pembrolizumab, Merck & Co., CQD, ASX, Fast track (FDA), PD-L1, Data, Autoimmune disease, Incidence, Patient, Head, Death, Quality of life, Merck, Neoplasm, IMM, Medical imaging

SYDNEY, AUSTRALIA, April 24, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces preliminary topline results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial evaluating eftilagimod alpha (efti) in combination with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) as first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma patients (1L HNSCC) with negative PD-L1 expression.

Key Points: 
  • Head and neck squamous cell carcinomas are a heterogenous disease that represent a high unmet medical need regardless of PD-L1 expression.
  • A total of 33 patients with recurrent or metastatic HNSCC have been enrolled into Cohort B.
  • The final number of evaluable patients in Cohort B is expected to be higher and additional data, including complete response rate, will be released together with Cohort A data.
  • Patients in Cohort A are stratified by CPS >1, CPS 1-19, and CPS >20, and the clinical results for these three CPS groups will be evaluated.

Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Wednesday, April 24, 2024
Poster, Pembrolizumab, Webcast, ASCO, Patient, Society, Head, Annual general meeting, Pharmaceutical industry

BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will present an oral abstract and poster at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 – June 4, 2024 in Chicago, IL.

Key Points: 
  • BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will present an oral abstract and poster at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 – June 4, 2024 in Chicago, IL.
  • The presentations will highlight the Company’s Phase 1 trials of its lead interleukin 2 (IL-2)-based biologics, CUE-101 in recurrent/metastatic head and neck cancer and CUE-102 in Wilms’ Tumor 1 positive recurrent/metastatic cancers.
  • The Company will host a Business Update call and webcast in June 2024 that will include a discussion on the clinical progress and associated data presented at ASCO on June 1 and June 4.
  • The oral abstract and poster presentations will be available in the Investor & Media section of the Company’s website at www.cuebiopharma.com under Scientific Publications and Presentations, following ASCO.

Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor

Retrieved on: 
Tuesday, April 23, 2024
Neuro-Oncology (journal), First grade, FDA, Society, University, BRAF V600, Day One, Hospital, Acne, Safety, Food, Biopharmaceutical, Conference call, Nausea, Insurance, Conference, Research, Webcast, Viral, Speech, Fatigue, Human, Disease, BRAF, Vomiting, Patient, Medicine, Headache, Event, Rash, Constipation, Diagnosis, Head, Neoplasm, Upper respiratory tract infection, PRS, Xeroderma, Fever, Caregiver, Ageing, Pharmaceutical industry

BRISBANE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a commercial-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved OJEMDA (tovorafenib), a type II RAF inhibitor, for the treatment of patients 6 months of age and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. This indication is approved under accelerated approval based on response rate and duration of response. With the approval, Day One received a rare pediatric disease priority review voucher from the FDA.

Key Points: 
  • With the approval, Day One received a rare pediatric disease priority review voucher from the FDA.
  • “We are very proud that our first approved medicine addresses this serious and life-threatening disease of childhood and adolescence.
  • BRAF is the most commonly altered gene in pLGG, with up to 75 percent of children having a BRAF alteration.
  • “This is a tremendous moment not only for Day One, but also for the broader pediatric brain tumor community.

Homes For Heroes Foundation Receives Multi Year Commitment From BMO

Retrieved on: 
Tuesday, April 23, 2024
Well, National security, Purpose, Housing, Veterans' affairs, Heart, Partnership, World War I, Life, Segment, Employment, National War Finance Committee, Military personnel, Canada Savings Bond, BMO, Social support, Organic, Good, Second, First, Organization, Head, Management

TORONTO, April 23, 2024 (GLOBE NEWSWIRE) -- Homes For Heroes Foundation today announced a $1.5 million donation from BMO – a long-time supporter of the Canadian Armed Forces and Canadian Veterans.

Key Points: 
  • TORONTO, April 23, 2024 (GLOBE NEWSWIRE) -- Homes For Heroes Foundation today announced a $1.5 million donation from BMO – a long-time supporter of the Canadian Armed Forces and Canadian Veterans.
  • “We are thrilled to begin a partnership with BMO in support of our charity’s mission to end the issue of Veteran homelessness.
  • BMO is a global company with a proven commitment to our military community and today’s announcement will go a long way in helping us achieve our mission,” noted Brad Field, President and CEO of Homes For Heroes Foundation .
  • “As the Official Bank of the Canadian Defence Community, BMO is proud to partner with the Homes for Heroes Foundation and help accelerate the Foundation’s National Veterans’ Village Program,” said Gayle Ramsay, Head, Everyday Banking, Segment & Customer Growth, BMO.

Shifting Regulations and Emerging Threats Cause Nearly a Third of CISOs to Consider Leaving Their Roles

Retrieved on: 
Tuesday, April 23, 2024
Head, RSA Conference, CISO, Conference, Pressure, CIO, Organization, Financial adviser

The survey, conducted by Wakefield Research on behalf of Devo, demonstrates that many CISOs feel uneasy about emerging regulations and new threats and also feel there is a general lack of understanding about the CISO role.

Key Points: 
  • The survey, conducted by Wakefield Research on behalf of Devo, demonstrates that many CISOs feel uneasy about emerging regulations and new threats and also feel there is a general lack of understanding about the CISO role.
  • Respondents to the survey reported they felt the pressure of their roles mounting on them.
  • More specifically:
    Nearly one in three (32%) of the CISOs surveyed think about leaving their roles because of the constantly changing threat and regulatory environment.
  • The regulatory landscape constantly shifts, with new country- and industry-specific regulations emerging regularly.

Garry Menzel joins GHO Capital as Operating Partner

Retrieved on: 
Tuesday, April 23, 2024
Diamond, Credit Suisse, Doctor of Philosophy, Goldman Sachs, Stanford University, University, DSM-IV codes, Partner, ADAP, M.B.A, Immunotherapy, Molecular biology, Patient, Operating partner, GHO, Clinical trial, Therapy, Health, Biotechnology, Head, Pharmaceutical industry

London, UK – 23 April 2024: Global Healthcare Opportunities, or GHO Capital Partners LLP (“GHO”), the European specialist investor in global healthcare, is pleased to announce the appointment of Dr. Garry Menzel as Operating Partner.

Key Points: 
  • London, UK – 23 April 2024: Global Healthcare Opportunities, or GHO Capital Partners LLP (“GHO”), the European specialist investor in global healthcare, is pleased to announce the appointment of Dr. Garry Menzel as Operating Partner.
  • As Operating Partner, Garry will leverage his extensive biotech industry experience in building innovative businesses to guide the GHO portfolio to deliver market leading services to the emerging biopharma space, as well as supporting GHO with deal origination across Europe and the US.
  • On behalf of the entire GHO team, we wish him a warm welcome.”
    Commenting on his new appointment, Garry Menzel, Operating Partner at GHO Capital, said: “Throughout my career, I have been committed to bringing forward the highest possible innovative standards for patients within the healthcare system whilst creating long-term investor value.
  • I am excited to support GHO Capital, as Europe’s leading healthcare specialist private equity firm, to pursue the same goal.